Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Standard vs Extended Dosing of Nivolumab or Pembrolizumab in Advanced Cancers
NCT04295863Phase 1Recruiting
- Sponsor
- University of Chicago
- Start
- Jun 2020
- Primary completion
- Apr 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of nivolumab and pembrolizumab in metastatic cancer, sponsored by University of Chicago. Primary endpoint: Noninferiority margin of extended interval dosing compared to standard dosing at 2 years. Started Jun 2020; status: recruiting.
02
Drugs
03
Conditions
metastatic cancer
Beyond the preview
Go deeper on NCT04295863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04295863.